Skip to main content
Download PDF

Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a meta-analysis

Annals of Clinical Microbiology and Antimicrobials volume 19, Article number: 53 (2020) Cite this article

Abstract

Background

The colonization of Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) in bloodstream infections (BSIs) has been increased dramatically worldwide, and it was associated with worse clinical outcomes in patients with malignancy. We performed the meta-analysis to investigate the prognosis and risk factors in BSIs caused by ESBL-PE in oncological patients.

Methods

PubMed, EMBASE, and Cochrane Library were searched for related studies. All-cause mortality was considered as the primary outcome. Subgroup analyses, meta-regression analyses, and sensitivity analysis were used to investigate heterogeneity and reliability in results.

Results

6,729 patients from 25 studies were eligible. Six studies enrolled oncological patients with BSIs caused by ESBL-PE only, while 19 studies both enrolled ESBL-PE and non-ESBL-PE infections. The results showed that BSIs caused by ESBL-PE in patients with malignancy was associated with higher mortality than non-ESBL-PE infections (RR = 2.21, 95% CI: 1.60–3.06, P < 0.001), with a significant between-study heterogeneity (I2 =78.3%, P < 0.001). Subgroup analyses showed that children (RR = 2.80, 95% CI: 2.29–3.43, P < 0.001) and hematological malignancy (RR = 3.20, 95% CI: 2.54–4.03, P < 0.001) were associated with a higher mortality. Severe sepsis/ septic shock, pneumonia, and ICU admission were the most common predictors of mortality.

Conclusions

Our study identified that BSIs caused by ESBL-PE in patients with malignancy were associated with worse clinical outcomes compared with non-ESBL-PE infections. Furthermore, children and hematological malignancy were associated with higher mortality. Severe sepsis/ septic shock, pneumonia, and ICU admission were the most common predictors of mortality.

Background

In recent years, the incidence of bloodstream infections (BSIs) caused by Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) has been increasing over time all over the world [1]. There is a growing body of evidence to show that BSIs caused by ESBL-PE are more worrisome in clinical practice. Extended-spectrum β-lactamases (ESBLs) mediates resistance to a wide variety of antibiotics, including third-generation cephalosporins, aminoglycosides, and quinolones. Furthermore, most of empirical antimicrobial regimens can not cover these pathogens [2, 3]. Therefore, the antimicrobial therapeutic regimens are often limited in these infections [1].

Patients with malignancy are more vulnerable to developing severe infection, including those caused by ESBL-PE since they are more likely to be immunocompromised due to chemotherapy, radiotherapy, surgery, invasive procedures, malnutrition, and malignancy itself [4, 5]. As a result, these infections have become significant therapeutic challenges for clinicians due to delayed initiation of chemotherapy, reduced standard dosage, prolonged hospitalization, increased financial burden on healthcare, and raised severe morbidity and mortality [3, 6]. Therefore, rapid initiation of appropriate antibiotic therapy is pivotal for oncological patients with BSIs caused by ESBL-PE, [4] while inappropriate empirical antibiotic treatment is associated with worse outcomes and survival [3].

Previous meta-analyses have investigated the prevalence of BSIs caused by ESBL-PE in patients with malignancy [7, 8]. However, there was no further analysis of clinical outcomes and risk factors in these populations. Therefore, we conducted this study to assess the prognosis and risk factors of BSIs due to ESBL-PE in patients with malignancy and provide updated evidence via meta-analysis.

Methods

Search strategy

Our meta-analysis was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [9]. We conducted an overall literature retrieval for PubMed, EMBASE, and Cochrane Library published up to 10 December 2019. Both MeSH terms and free words were used to search for title/ abstract. Our search terms were: “(ESBL OR (extended-spectrum beta-lactamase) OR (extended-spectrum β-lactamase)) AND (tumor OR neoplasia OR malignancy OR cancer OR carcinoma OR sarcoma OR leukemia OR leukaemia OR lymphoma OR hematolog* OR haematolog* OR oncolog*)”. We manually screened other relevant studies and reference lists. The search was performed independently by two investigators (AM Jiang and N Liu).

Study selection

Studies were considered as eligible based on the following criteria: [1] population: patients with solid or hematological malignancies; [2] intervention (exposure): BSIs caused by ESBL-PE; [3] comparison: BSIs caused by non-ESBL-PE; [4] outcome: the mortality of BSIs. Literature that satisfied the following criteria were excluded: [1] letters, case reports, editorials, expert opinion or reviews without original data; [2] overlapping or duplicate data; [3] incomplete data about outcomes; [4] not English literatures; [5] the sample size of BSIs caused by ESBL-PE in oncological patients less than 10; [6] studies only focusing on risk factors for ESBL-PE infections.

Data extraction and quality assessment

Two investigators (AM Jiang and N Liu) independently extracted the data using a standardized approach. Any disagreement in the study selection and data extraction phases was resolved through discussion with the third investigator (R Zhao). The following data information was retrieved from each article: first author’s name, year of publication, country, study population, infection type of BSIs, the total number of screened subjects, the total number of ESBL-PE caused BSIs, the total number of BSIs caused death and ESBL-PE BSIs caused death, and ESBL detection method. The data was extracted from texts or tables in articles. Newcastle Ottawa Quality Assessment Scale (NOS) was used in our research to assess the quality of selected studies [10]. The scale included three aspects: selection, comparability, and outcome. Studies that scored more than five were considered of high quality.

Definitions and study outcomes

Neutropenia was defined as an absolute neutrophil count of < 500 neutrophils/mm3 [11].

Empirical antibiotics treatment was considered inappropriate once the antibiotics could not suppress the activity of the isolated pathogens according to the results of antimicrobial susceptibility tests during the first 24 h after the blood culture was obtained [11].

The all-cause mortality at the end of the study and the predictors in BSIs due to ESBL-PE in patients with malignancy were the primary outcomes in the study [12].

Statistical analysis

The RRs and 95% CIs for mortality were calculated to assess the outcomes of BSIs caused by ESBL-PE in oncological patients. All results were depicted as forest plots. Heterogeneity was assessed using Cochran’s Q test and the I2 statistic test. When the heterogeneity was statistically significant (P < 0.05 and I2 > 50%), a random-effects model was applied to obtain the pooled RRs; otherwise, a fixed-effects model was performed. Subgroup analyses and meta-regression analyses were conducted to explore the sources of heterogeneity. We also performed a sensitivity analysis to evaluate the quality and stability of results by omitting one study in each turn. Begg’s test and Egger’s test were used to assess the publication bias. Statistical tests were two-tailed at the significance level of P < 0.05. All analyses were used with STATA V.14.0 (Stata Corporation, College Station, TX).

Results

Study characteristics and quality assessment

Our literature search identified 1,260 studies. After excluding repeated records and the initial screening based on titles and abstracts, 25 articles were eligible in this study. Of these, six studies enrolled oncological patients with BSIs caused by ESBL-PE only, while 19 studies both enrolled ESBL-PE and non-ESBL-PE infections. Of the 25 studies, there were eight prospective cohort studies, 14 retrospective cohort studies, and three case–control studies. All included studies were published between 2009 and 2019, and there were six studies published in 2019, accounting for 24%. There were 15 studies conducted in Asia, seven studies conducted in Europe, and three studies were conducted in North America. The detailed flow chart of the study selection process was described in Fig. 1. Table 1 summarized the characteristics of 25 selected studies. The majority of the included studies had a NOS score of more than 5 points, and 21 studies included in this article were high-quality studies. Additional file 1: Table S1 presented the results of the quality assessment.

Fig. 1
figure 1

Flow chart of the eligible studies for meta-analysis

Full size image
Table 1 Characteristics of the studies and their populations included in the review
Full size table

Mortality

In all the studies, the time of death records was not similar. The majority of studies used 30-day mortality to evaluate the clinical outcomes of BSIs caused by ESBL-PE in patients with malignancy, [13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29] only one study did not report a particular time of death [30]. In studies that only enrolled oncological patients with ESBL-PE infections, the mortality of BSIs varied from 10.7 to 31.0%. However, the mortality of BSIs varied from 4.8 to 51.0% in studies that both enrolled ESBL-PE and non-ESBL-PE infections oncological patients, respectively. We finally included 19 studies that enrolled both ESBL-PE and non-ESBL-PE infected oncological patients into analyses to estimate the mortality of BSIs caused by ESBL-PE in patients with malignancy. The results showed that in patients with malignancy, ESBL-PE infections were associated with a higher mortality risk from BSIs than non-ESBL-PE infections (RR = 2.21, 95% CI: 1.60–3.06, P < 0.001) (Fig. 2), with a significant between-study heterogeneity (I2 = 78.3%, P < 0.001).

Fig. 2
figure 2

Forest plot of mortality in BSIs due to ESBL-PE among patients with malignancy. RR relative risk, CI confidence interval, BSIs bloodstream infections, Weights are from random-effects analysis. The size of the squares is analogous to the study's weight. Diamonds represent the pooled RRs and their confidence interval

Full size image

Subgroup analyses and meta-regression analyses

Subgroup analyses in all selected studies were conducted by study design, region, study population, malignancy type, FN, ESBL detection methods, and NOS score. Most of the subgroups (study design, region, study population, malignancy type, and ESBL detection methods) were consistent with the overall trend and showed statistically significant increases, except for the subgroup without FN, and the subgroup with NOS score < 6. The subgroup analyses suggested that study region was identified as potential sources of the heterogeneity (test for subgroup difference: P = 0.014), and the RR of mortality in studies from Asia (RR = 1.49, 95% CI: 1.22–1.82) was lower compared with Europe and North America, with no evidence of heterogeneity (I2 = 27.3%, P = 0.177). The detailed information was in Table 2 and Additional file 1: Figure S1.

Table 2 Subgroup analysis for meta-analysis of mortality
Full size table

Sensitivity analysis and publication bias

We then carried out the sensitivity analysis by omitting each study in turn. As summarized in Additional file 1: Figure S2, the pooled RRs and 95% CIs of mortality ranged from 2.03 (1.53–2.68) to 2.36 (1.72–3.25). The results of the sensitivity analysis show that our results are stable and reliable since there were no individual studies influenced the overall results. Begg’s test and Egger’s test showed no evidence of publication bias (P = 0.944 for Begg’s test; P = 0.538 for Egger’s test, respectively) (Additional file 1: Figure S3).

Predictors of mortality in BSIs caused by ESBL-PE among patients with malignancy

We then summarized the risk factors for BSIs caused by ESBL-PE in patients with malignancy. It showed that the most commonly studied risk factors for BSIs caused by ESBL-PE in patients with malignancy were age, gender, ESBL production, neutropenia, inadequate initial antimicrobial treatment, ICU admission, intra-abdominal infection, pneumonia, Pitt bacteremia score, severe sepsis/ septic shock, solid tumor, and concurrent corticosteroid therapy. However, metastasis and mechanical ventilation were the least studied variables. We also found that the most common independent risk factors of mortality were severe sepsis/ septic shock, pneumonia, ICU admission, and neutropenia. At the same time, indwelling urinary catheter, [23] pneumonia, [31] Pitt bacteremia score, [32] and severe sepsis/ septic shock [31] were the most common independent risk factors of mortality in studies that only enrolled patients with BSIs caused by ESBL-PE. In studies that both included ESBL-PE and non-ESBL-PE infections, severe sepsis/ septic shock, [14, 16, 18, 19, 22, 24, 28, 33] ICU admission, [14, 19, 27, 33, 34] neutropenia, [13, 14, 24, 35] and pneumonia [14, 16, 21, 28] were the most commonly investigated independent risk factors, respectively. Interestingly, there were only three studies [13, 14, 16] identified that ESBL production was associated with unfavorable outcomes in these patients. The detailed information was in Table 3.

Table 3 The most commonly studied characteristics as predictors of mortality in the reviewed studies
Full size table

Discussion

Over the past ten years, the colonization and prevalence of ESBL-PE infections have continued to increase rapidly all over the world,[36] and these infections generally associated with worse clinical outcomes, prolonged hospitalization, extra healthcare burden, and delayed initiation of treatment for malignancy [3]. Patients with malignancy are more easily to develop BSIs caused by ESBL-PE since oncological patients are easily immunocompromised due to a series of mechanisms as mentioned before [5]. Therefore, timely and appropriate empirical antimicrobial therapeutic regimen is pivotal for patients with malignancy who developed BSIs caused by ESBL-PE [5].

In this meta-analysis, we included 19 studies that both enrolled oncological patients with ESBL-PE and non-ESBL-PE infections, and the results showed that the mortality in BSIs caused by ESBL-PE among patients with malignancy was higher compared with non-ESBL-PE infections (RR = 2.21, 95% CI: 1.60–3.06, P < 0.001). Consistent with our findings, Trecarichi EM et al. reported that ESBL-PE caused BSIs in patients with malignancy was associated with high mortality compared with non-ESBL-PE infections [13, 14, 16]. This result suggests that we should think highly of BSIs caused by ESBL-PE in patients with malignancy during hospitalization, and the rapid initiation of antibiotics treatment should be considered as early as possible once it was recognized.

The results of the subgroup analyses showed that the mortality of ESBL-PE BSIs varies from different regions. We found that the mortality in North America and Europe was higher than in Asia. It could be explained by the fact that the majority of studies were conducted in Asia, and the study region was confirmed as a source of heterogeneity after further meta-regression analyses. Alevizakos M et al. reported that ESBL-PE are the causative agents of approximately 10.0% BSIs among patients with malignancy in Southeast Asia, and it has been associated with increased mortality in these subjects compared with Europe and America [37]. Therefore, more relevant studies need to be included in the future to draw a more reliable conclusion. We also found that children and hematological malignancy were also associated with worse prognosis in BSIs caused by ESBL-PE. It may be attributed to the fact that the included children population were mainly diagnosed with hematological malignancies, which were more vulnerable to develop immunosuppression, prolonged neutropenia, and septic shock [38, 39]. Interestingly, we observed that FN was not associated with higher mortality in oncological patients with BSIs caused by ESBL-PE. This can be explained by the fact that only three studies included patients with FN. Besides, some studies only enrolled a subset of FN patients, but the data were not accessible to analyze [13, 14, 16, 21, 24, 25, 30, 34, 40]. Among these studies, Kang CI et al. reported that FN/ neutropenia was not the risk factor for mortality in BSIs caused by ESBL-PE among patients with malignancy [14, 16, 21, 24]. Hence, the accuracy of the conclusion needs to be further confirmed. The combined RR of sensitivity analysis further confirmed the stability of the results. Besides, the meta-regression analyses also suggested that the study region might be the source of heterogeneity in this meta-analysis, despite other relevant factors such as age, comorbidities, and antimicrobial treatment regimens cannot be analyzed due to lack of relevant data. However, Begg’s test and Egger’s test showed there was no evidence of publication bias in our study.

In our study, approximately 72.0% of studies analyzed the relationship between age and mortality of BSIs caused by ESBL-PE in patients with malignancy. However, there were no studies that identified age as independent predictor. Furthermore, more than 50.0% of studies concluded that severe sepsis/ septic shock, pneumonia, and ICU admission were the most common independent risk factors in mortality. Besides, fewer studies confirmed that neutropenia was more common in patients who died. According to a study conducted by Vardakas KZ et al., they reported that underlying diseases and severity scores were the most commonly identified prognostic factors of mortality in patients with infections due to multi-drug resistant Gram-negative bacteria (MDRGNB) [12]. Similar to the previous study, [12] we also found that severe sepsis/ septic shock was the most common risk factor in mortality. However, only fewer studies concluded that the Pitt bacteremia score and Charlson Index Score (CCI) were more common in patients who died. An interesting finding of our study is that only three studies confirmed ESBL production was an independent risk factor in mortality. Rottier WC et al. reported that ESBL production was associated with higher mortality compared with bacteremia with non-ESBL-PE [41]. This could be due to the small sample size of some studies we included in this study. Therefore, more prospective multicenter studies and clinical trials were urgently needed in the future to provide sufficient evidence.

To our knowledge, this is the first study that evaluated the clinical outcomes and risk factors in BSIs caused by ESBL-PE among patients with malignancy using Meta-analysis. However, our study has several limitations. First, all of the included articles were observational studies and published in English. Besides, high-estimated heterogeneity was observed, which is probably related to different design, study region, and study population. Moreover, some studies included oncological patients with FN, but the data was not available for subgroup analysis. Therefore, the clinical outcomes of BSIs caused by ESBL-PE in these patients should be further validated since these patients are more vulnerable to severe infections. To sum up, clinical conclusions need to be comprehensive assessment in combination with other indicators, and more sample sizes and studies need to be added to verify our results.

Conclusions

In summary, our study provided a systematic analysis for the prognosis and risk factors of BSIs due to ESBL-PE in oncological patients. Our findings suggested that BSIs caused by ESBL-PE in patients with malignancy were associated with worse clinical outcomes compared with non-ESBL-PE infections. Furthermore, children and hematological malignancy were associated with higher mortality. We also identified that severe sepsis/ septic shock, pneumonia, and ICU admission were the most common predictors of mortality. Large-scale and prospective studies are warranted to verify the results of our study.

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Abbreviations

ESBL-PE:

Extended-spectrum β-lactamase-producing Enterobacteriaceae

BSI:

Bloodstream infection

SC:

Single-center

MC:

Multicenter

NR:

Not reported

FN:

Febrile neutropenia

RR:

Relative risk

CI:

Confidence interval

NOS:

Newcastle–Ottawa scale

CCI:

Charlson Index Score

ICU:

Intensive care unit

References

  1. Alevizakos M, Gaitanidis A, Andreatos N, Arunachalam K, Flokas ME, Mylonakis E. Bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae among patients with malignancy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017a;50(5):657–63.

    Article  CAS  PubMed  Google Scholar 

  2. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients—review of the literature from a clinical perspective. Crit Rev Microbiol. 2016;42(1):1–16.

    Article  CAS  PubMed  Google Scholar 

  4. Alevizakos M, Karanika S, Detsis M, Mylonakis E. Colonisation with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016a;48(6):647–54.

    Article  CAS  PubMed  Google Scholar 

  5. Gudiol C, Aguado JM, Carratala J. Bloodstream infections in patients with solid tumors. Virulence. 2016;7(3):298–308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ndir A, Diop A, Ka R, Faye PM, Dia-Badiane NM, Ndoye B, et al. Infections caused by extended-spectrum beta-lactamases producing Enterobacteriaceae: clinical and economic impact in patients hospitalized in 2 teaching hospitals in Dakar. Senegal Antimicrob Resist Infect Control. 2016;5:13.

    Article  PubMed  Google Scholar 

  7. Alevizakos M, Karanika S, Detsis M, Mylonakis E. Colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016b;48(6):647–54.

    Article  CAS  PubMed  Google Scholar 

  8. Alevizakos M, Gaitanidis A, Andreatos N, Arunachalam K, Flokas ME, Mylonakis E. Bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017b;50(5):657–63.

    Article  CAS  PubMed  Google Scholar 

  9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clin Res Ed). 2009;339:b2700.

    Article  Google Scholar 

  10. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

    Article  PubMed  Google Scholar 

  11. Ha YE, Kang CI, Cha MK, Park SY, Wi YM, Chung DR, et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. 2013a;42(5):403–9.

    Article  CAS  PubMed  Google Scholar 

  12. Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect. 2013;66(5):401–14.

    Article  PubMed  Google Scholar 

  13. Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, et al. Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58(4):299–307.

    Article  PubMed  Google Scholar 

  14. Kang CI, Chung DR, Ko KS, Peck KR, Song JH. Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol. 2012;91(1):115–21.

    Article  CAS  PubMed  Google Scholar 

  15. Wu UI, Chen WC, Yang CS, Wang JL, Hu FC, Chang SC, et al. Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis. IJID. 2012;16(1):e47-52.

    CAS  PubMed  Google Scholar 

  16. Ha YE, Kang CI, Cha MK, Park SY, Wi YM, Chung DR, et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. 2013b;42(5):403–9.

    Article  CAS  PubMed  Google Scholar 

  17. Kang CI, Wi YM, Ko KS, Chung DR, Peck KR, Lee NY, et al. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy. Scand J Infect Dis. 2013;45(7):519–25.

    Article  CAS  PubMed  Google Scholar 

  18. Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome. Ann Hematol. 2013;92(4):533–41.

    Article  PubMed  CAS  Google Scholar 

  19. Bodro M, Gudiol C, Garcia-Vidal C, Tubau F, Contra A, Boix L, et al. Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. Support Care Cancer . 2014;22(3):603–10.

    Article  PubMed  Google Scholar 

  20. Han SB, Jung SW, Bae EY, Lee JW, Lee DG, Chung NG, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children. Microb Drug Resist . 2015;21(2):244–51.

    Article  CAS  PubMed  Google Scholar 

  21. Cattaneo C, Zappasodi P, Mancini V, Annaloro C, Pavesi F, Skert C, et al. Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel). Ann Hematol. 2016;95(12):1955–63.

    Article  PubMed  Google Scholar 

  22. Ma J, Li N, Liu Y, Wang C, Liu X, Chen S, et al. Antimicrobial resistance patterns, clinical features, and risk factors for septic shock and death of nosocomial e coli bacteremia in adult patients with hematological disease. Medicine . 2017;96(21):e6959.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, et al. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol. 2018;97(9):1717–26.

    Article  CAS  PubMed  Google Scholar 

  24. Çeken S, İskender G, Gedik H, Duygu F, Mert D, Kaya AH, et al. Risk factors for bloodstream infections due to extended-spectrum β-lactamase producing enterobacteriaceae in cancer patients. J Infect Dev Countries. 2018;12(4):265–72.

    Article  CAS  Google Scholar 

  25. Islas-Muñoz B, Volkow-Fernández P, Ibanes-Gutiérrez C, Villamar-Ramírez A, Vilar-Compte D, Cornejo-Juárez P. Bloodstream infections in cancer patients. Risk factors associated with mortality. Int J Infect Dis. 2018;71:59–64.

    Article  PubMed  Google Scholar 

  26. Isendahl J, Giske CG, Tegmark Wisell K, Ternhag A, Nauclér P. Risk factors for community-onset bloodstream infection with extended-spectrum β-lactamase-producing Enterobacteriaceae: national population-based case–control study. Clin Microbiol Infect. 2019;25(11):1408–14.

    Article  CAS  PubMed  Google Scholar 

  27. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65(2):333–41.

    Article  CAS  PubMed  Google Scholar 

  28. Kim SJ, Park KH, Chung JW, Sung H, Choi SH, Choi SH. Prevalence and impact of extended-spectrum β-lactamase production on clinical outcomes in cancer patients with enterobacter species bacteremia. Korean J Intern Med. 2014;29(5):637–46.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Alvarez R, la Maestro-de Calle G, et al. Efficacy of beta-lactam/beta-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae in hematological patients with neutropenia. Antimicrob Agents Chemother. 2017;61(8):e00164-e217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Namikawa H, Yamada K, Yamairi K, Shibata W, Fujimoto H, Takizawa E, et al. Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam. Diagn Microbiol Infect Dis. 2019;94(3):287–92.

    Article  CAS  PubMed  Google Scholar 

  31. Wang SS, Lee NY, Hsueh PR, Huang WH, Tsui KC, Lee HC, et al. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Microbiol Immunol Infect. 2011;44(4):282–8.

    Article  CAS  PubMed  Google Scholar 

  32. Benanti GE, Brown ART, Shigle TL, Tarrand JJ, Bhatti MM, McDaneld PM, et al. Carbapenem versus cefepime or piperacillin-tazobactam for empiric treatment of bacteremia due to extended-spectrum-beta-lactamase-producing escherichia coli in patients with hematologic malignancy. Antimicrob Agents Chemother. 2019. https://doi.org/10.1128/AAC.01813-18.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Zhang Q, Gao HY, Li D, Li Z, Qi SS, Zheng S, et al. Clinical outcome of Escherichia coli bloodstream infection in cancer patients with/without biofilm formation: a single-center retrospective study. IDR. 2019;12:359–71.

    Article  CAS  Google Scholar 

  34. Metan G, Demiraslan H, Kaynar LG, Zararsiz G, Alp E, Eser B. Factors influencing the early mortality in haematological malignancy patients with nosocomial Gram negative bacilli bacteraemia: a retrospective analysis of 154 cases. Brazilian J Infect Dis . 2013;17(2):143–9.

    Article  Google Scholar 

  35. Kim YJ, Jung SM, Kang J, Ryoo SM, Sohn CH, Seo DW, et al. Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia. Intern Emerg Med. 2019;14(3):433–40.

    Article  PubMed  Google Scholar 

  36. Pitout JDD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159–66.

    Article  CAS  PubMed  Google Scholar 

  37. Alevizakos M, Mylonakis E. Colonization and infection with extended-spectrum beta-lactamase producing Enterobacteriaceae in patients with malignancy. Expert Rev Anti Infect Ther. 2017;15(7):653–61.

    Article  CAS  PubMed  Google Scholar 

  38. Schelenz S, Nwaka D, Hunter PR. Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance. J Antimicrob Chemother. 2013;68(6):1431–8.

    Article  CAS  PubMed  Google Scholar 

  39. Satlin MJ, Cohen N, Ma KC, Gedrimaite Z, Soave R, Askin G, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect. 2016;73(4):336–45.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Cornejo-Juarez P, Perez-Jimenez C, Silva-Sanchez J, Velazquez-Acosta C, Gonzalez-Lara F, Reyna-Flores F, et al. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum beta-lactamase bloodstream infection in hematological malignancies. PLoS ONE. 2012;7(4):e35780.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67(6):1311–20.

    Article  CAS  PubMed  Google Scholar 

  42. Ben-Chetrit E, Eldaim MA, Bar-Meir M, Dodin M, Katz DE. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia. Int J Antimicrob Agents. 2019;53(4):423–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Author notes

  1. Ai-Min Jiang and Na Liu contributed equally to this work.

Authors and Affiliations

  1. Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, People’s Republic of China

    Ai-Min Jiang, Na Liu, Hao-Ran Zheng, Xue Chen, Chao-Xin Fan, Rui Zhang, Xiao-Qiang Zheng, Xiao Fu, Yu Yao & Tao Tian

  2. Department of Nutrition and Food Hygiene, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Rui Zhao

Authors
  1. Ai-Min Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Na Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rui Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hao-Ran Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xue Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chao-Xin Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiao-Qiang Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiao Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yu Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tao Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TT and YY conceived the study. AMJ, NL, and RZ performed the search, extracted the data and performed the analyses. HRZ, XC, CXF, and RZ participated in the study design and helped with the data analyses. XQZ and XF participated in the study design and manuscript revision. All authors interpreted the data, and AMJ and NL wrote the paper. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yu Yao or Tao Tian.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1:

Table S1. Quality assessment conducted according to the NOS for all included studies. Figure S1. Forest plots of mortality in BSIs due to ESBL-PE among patients with malignancy by different subgroups. (a) study design; (b) region; (c) population; (d) malignancy type (e) FN; (f) ESBL detection methods; (g) NOS score. Figure S2. Sensitivity analysis of mortality in BSIs due to ESBL-PE among patients with malignancy. Figure S3. Tests for publication bias. a Begg's funnel plot with pseudo 95% confidence limits; b Egger's publication bias plot.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, AM., Liu, N., Zhao, R. et al. Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a meta-analysis. Ann Clin Microbiol Antimicrob 19, 53 (2020). https://doi.org/10.1186/s12941-020-00395-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12941-020-00395-7

Keywords

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us